Statins in the prevention and treatment of Alzheimer disease

被引:72
作者
Crisby, M [1 ]
Carlson, LA
Winblad, B
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Neurotec Div Geriatr Med, Alzheimer Dis Res Ctr, S-14186 Stockholm, Sweden
[2] Karolinska Inst, King Gustaf V Res Inst, Stockholm, Sweden
关键词
cholesterol; statins; Alzheimer disease;
D O I
10.1097/00002093-200207000-00001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD). Treatment of hypercholesterolemia and other vascular risk factors may have great implications in the prevention of AD. Recent findings illustrate that the sterol metabolism in the brain is an active process, well controlled and regulated by 24-hydroxylase, an enzyme that is uniquely expressed in the brain. The use of statins in ischemic heart disease (IHD) has proven to be a phenomenal advance in pharmacological disease prevention and treatment. A growing body of evidence, suggest that statins exhibit additional benefits that are independent of their cholesterol-lowering actions. Statin treatment has also considerable effect in prevention of ischemic stroke. In animal models of ischemic stroke, statins have proven to reduce infarct size through up-regulation of endothelial nitric oxide synthases. Data from recent observational studies have revealed a potential role for statins in prevention of AD. The following review comments the processes leading to dementia including the involvement of cholesterol regulation, cerebral circulation and inflammation in development of dementia. The mechanisms by which statins may be beneficial in controlling these processes is discussed.
引用
收藏
页码:131 / 136
页数:6
相关论文
共 70 条
  • [31] Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia -: Evidence that simvastatin affects cholesterol metabolism in the human brain
    Locatelli, S
    Lütjohann, D
    Schmidt, HHJ
    Otto, C
    Beisiegel, U
    von Bergmann, K
    [J]. ARCHIVES OF NEUROLOGY, 2002, 59 (02) : 213 - 216
  • [32] Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury
    Lomnitski, L
    Kohen, R
    Chen, Y
    Shohami, E
    Trembovler, V
    Vogel, T
    Michaelson, DM
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 56 (04) : 669 - 673
  • [33] Lütjohann D, 2000, J LIPID RES, V41, P195
  • [34] MATTILA KM, 1994, ACTA NEUROL SCAND, V89, P192
  • [35] Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture
    Michikawa, M
    Fan, QW
    Isobe, I
    Yanagisawa, K
    [J]. JOURNAL OF NEUROCHEMISTRY, 2000, 74 (03) : 1008 - 1016
  • [36] Pore formation by the cytotoxic islet amyloid peptide amylin
    Mirzabekov, TA
    Lin, MC
    Kagan, BL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (04) : 1988 - 1992
  • [37] THE RELATIONSHIP BETWEEN SENILE PLAQUES AND CEREBRAL BLOOD-VESSELS IN ALZHEIMERS-DISEASE AND SENILE DEMENTIA - MORPHOLOGICAL MECHANISM OF SENILE PLAQUE PRODUCTION
    MIYAKAWA, T
    SHIMOJI, A
    KURAMOTO, R
    HIGUCHI, Y
    [J]. VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1982, 40 (02) : 121 - 129
  • [38] Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO
  • [39] 2-9
  • [40] Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types
    NegreAminou, P
    vanVliet, AK
    vanErck, M
    vanThiel, GCF
    vanLeeuwen, REW
    Cohen, LH
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1997, 1345 (03): : 259 - 268